Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suramin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | STAT1 | P42224 | 2/20 | 1.00 |
| ▸ | STAT5A | P42229 | 2/20 | 1.00 |
| ▸ | STAT5B | P51692 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501849 | 0.88 | P2RY11 (0.79) | RECQLKMT2AHSD17B10TDP1MAPT | |
| SCHEMBL29438489 | 0.86 | P2RY11 (0.75) | RECQLKMT2AHSD17B10TDP1MAPT | |
| Suramin SCHEMBL3161 | 0.85 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1MAPT | |
| Suramin SCHEMBL30552218 | 0.85 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1MAPT | |
| Suramin SCHEMBL30312075 | 0.85 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1MAPT | |
| Suramin SCHEMBL29357785 | 0.85 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1MAPT | |
| Suramin SCHEMBL29371906 | 0.85 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1MAPT | |
| SCHEMBL21686991 | 0.83 | P2RY11 (0.95) | RECQLKMT2AHSD17B10TDP1MAPT | |
| SCHEMBL11406414 | 0.82 | P2RY11 (0.78) | RECQLKMT2AHSD17B10TDP1MAPT | |
| SCHEMBL11474334 | 0.81 | P2RY11 (0.76) | RECQLKMT2AHSD17B10TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2902 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| CN-119770468-A | Use of sodium suramin for preventing and/or treating radiation intestinal injury | 中国人民解放军军事科学院军事医学研究院 | 2025-04-08 | — | — | CN | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| EP-4508211-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | Caribou Biosciences, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| CN-118974253-A | Therapeutic application of CRISPR V-type system | 卡里布生物科学公司 | 2024-11-15 | — | — | CN | claimed |
| CN-116115595-B | Application of suramin in prevention and treatment of spring viremia virus (SVCV) infection of carp | 华中农业大学 | 2024-10-29 | — | — | CN | claimed |
| EP-0794784-A1 | COMBINATION CHEMOTHERAPY OF SURAMIN AND A VINCA-ALKALOID OR ESTRAMUSTINE | WARNER-LAMBERT COMPANY (US) | 1997-09-17 | — | — | EP | claimed |
| US-5597830-A | Combination chemotherapy | WARNER-LAMBERT COMPANY (US) | 1997-01-28 | — | — | US | claimed |
| EP-0722715-A1 | Cosmetic compositions containing lactate dehydrogenase inhibitors | UNILEVER PLC (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1996019226-A1 | COMBINATION CHEMOTHERAPY OF SURAMIN AND A VINCA-ALKALOID OR ESTRAMUSTINE | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | claimed |
| EP-0489102-A4 | PHARMACEUTICAL COMPOSITIONS CONTAINING AROMATIC POLYMERS AND THERAPEUTIC METHODS USING THE SAME | — | 1992-08-12 | — | — | EP | claimed |
| EP-0489102-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AROMATIC POLYMERS AND THERAPEUTIC METHODS USING THE SAME | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-06-10 | — | — | EP | claimed |
| WO-1991013624-A1 | ENDOGENOUS, SURAMIN-INDUCED, SULFATED GLYCOSAMINOGLYCANS AS ANTI-CANCER AGENTS IN HUMANS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-09-19 | — | — | WO | claimed |
| WO-1991003226-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING AROMATIC POLYMERS AND THERAPEUTIC METHODS USING THE SAME | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-03-21 | — | — | WO | claimed |
| EP-0354714-A2 | Pharmaceutical compositions containing polyaromatic compounds | HADASSAH MEDICAL ORGANIZATION (IL) | 1990-02-14 | — | — | EP | claimed |
| EP-0354818-A2 | Pharmaceutical compositions containing polyaromatic compounds as active ingredient and their use | HADASSAH MEDICAL ORGANIZATION (IL) | 1990-02-14 | — | — | EP | claimed |